Perirenal hematoma associated with bevacizumab treatment

Hidetoshi Hayashi, Isamu Okamoto, Kazuhiko Nakagawa

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We now describe the first example of a patient who developed perirenal hematoma during the course of bevacizumab-containing chemotherapy. A 59-years-old woman with metastatic rectal cancer treated with bevacizumab, who developed low back pain after 11 cycles of chemotherapy. CT-scan was consistent with perirenal hematoma and discontinuation of bevacizumab resulted in symptomatic improvement. Nontraumatic perirenal hematoma is a rare condition that can cause shock in severe cases. Given that several types of bleeding complication are known to be associated with bevacizumab treatment, we concluded that bevacizumab likely contributed to the perirenal hematoma in this case. Although the appropriate modification of bevacizumab treatment in the setting of perirenal hematoma is still unclear, physicians should be aware of this potential bevacizumab-associated bleeding complication.

Original languageEnglish
Pages (from-to)808-809
Number of pages2
JournalInvestigational New Drugs
Volume30
Issue number2
DOIs
Publication statusPublished - Apr 1 2012
Externally publishedYes

Fingerprint

Hematoma
Therapeutics
Hemorrhage
Drug Therapy
Rectal Neoplasms
Low Back Pain
Bevacizumab
Shock
Physicians

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Oncology

Cite this

Perirenal hematoma associated with bevacizumab treatment. / Hayashi, Hidetoshi; Okamoto, Isamu; Nakagawa, Kazuhiko.

In: Investigational New Drugs, Vol. 30, No. 2, 01.04.2012, p. 808-809.

Research output: Contribution to journalArticle

Hayashi, Hidetoshi ; Okamoto, Isamu ; Nakagawa, Kazuhiko. / Perirenal hematoma associated with bevacizumab treatment. In: Investigational New Drugs. 2012 ; Vol. 30, No. 2. pp. 808-809.
@article{5b51e9e2fe564480952e1959122bfe8b,
title = "Perirenal hematoma associated with bevacizumab treatment",
abstract = "We now describe the first example of a patient who developed perirenal hematoma during the course of bevacizumab-containing chemotherapy. A 59-years-old woman with metastatic rectal cancer treated with bevacizumab, who developed low back pain after 11 cycles of chemotherapy. CT-scan was consistent with perirenal hematoma and discontinuation of bevacizumab resulted in symptomatic improvement. Nontraumatic perirenal hematoma is a rare condition that can cause shock in severe cases. Given that several types of bleeding complication are known to be associated with bevacizumab treatment, we concluded that bevacizumab likely contributed to the perirenal hematoma in this case. Although the appropriate modification of bevacizumab treatment in the setting of perirenal hematoma is still unclear, physicians should be aware of this potential bevacizumab-associated bleeding complication.",
author = "Hidetoshi Hayashi and Isamu Okamoto and Kazuhiko Nakagawa",
year = "2012",
month = "4",
day = "1",
doi = "10.1007/s10637-010-9545-9",
language = "English",
volume = "30",
pages = "808--809",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Perirenal hematoma associated with bevacizumab treatment

AU - Hayashi, Hidetoshi

AU - Okamoto, Isamu

AU - Nakagawa, Kazuhiko

PY - 2012/4/1

Y1 - 2012/4/1

N2 - We now describe the first example of a patient who developed perirenal hematoma during the course of bevacizumab-containing chemotherapy. A 59-years-old woman with metastatic rectal cancer treated with bevacizumab, who developed low back pain after 11 cycles of chemotherapy. CT-scan was consistent with perirenal hematoma and discontinuation of bevacizumab resulted in symptomatic improvement. Nontraumatic perirenal hematoma is a rare condition that can cause shock in severe cases. Given that several types of bleeding complication are known to be associated with bevacizumab treatment, we concluded that bevacizumab likely contributed to the perirenal hematoma in this case. Although the appropriate modification of bevacizumab treatment in the setting of perirenal hematoma is still unclear, physicians should be aware of this potential bevacizumab-associated bleeding complication.

AB - We now describe the first example of a patient who developed perirenal hematoma during the course of bevacizumab-containing chemotherapy. A 59-years-old woman with metastatic rectal cancer treated with bevacizumab, who developed low back pain after 11 cycles of chemotherapy. CT-scan was consistent with perirenal hematoma and discontinuation of bevacizumab resulted in symptomatic improvement. Nontraumatic perirenal hematoma is a rare condition that can cause shock in severe cases. Given that several types of bleeding complication are known to be associated with bevacizumab treatment, we concluded that bevacizumab likely contributed to the perirenal hematoma in this case. Although the appropriate modification of bevacizumab treatment in the setting of perirenal hematoma is still unclear, physicians should be aware of this potential bevacizumab-associated bleeding complication.

UR - http://www.scopus.com/inward/record.url?scp=84862279059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862279059&partnerID=8YFLogxK

U2 - 10.1007/s10637-010-9545-9

DO - 10.1007/s10637-010-9545-9

M3 - Article

C2 - 20865298

AN - SCOPUS:84862279059

VL - 30

SP - 808

EP - 809

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -